Protocol H6Q-MC-S034(a) randomized, double-blind, phase 2 study of pemetrexed + carboplatin + bevacizumab + enzastaurin versus pemetrexed + carboplatin + bevacizumab + placebo in chemonaive patients with stage IIIB or IV non-small cell lung cancer

Trial Profile

Protocol H6Q-MC-S034(a) randomized, double-blind, phase 2 study of pemetrexed + carboplatin + bevacizumab + enzastaurin versus pemetrexed + carboplatin + bevacizumab + placebo in chemonaive patients with stage IIIB or IV non-small cell lung cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Enzastaurin (Primary) ; Bevacizumab; Carboplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 21 Jan 2011 Primary endpoint 'Progression-free-survival-duration' has not been met
    • 27 Sep 2010 Results published in the Journal of Thoracic Oncology.
    • 30 May 2009 Results reported at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top